Contact
How to shop
Delivery
Shopping guide
Biosimilarity
The FDA Perspective
English
189 b
30-day return policy
Customers also purchased
/
Paperback
8 130
Ft
Summary:
The focus of this book is on how the U.S. FDA will approve biosimilar drugs, as learned from recent approvals by the FDA. Understanding the limitations of the statutory limits and non-inferiority testing are presented as tools to obviate patient trials and minimize testing of immunogenicity. An in-depth scientific, mathematical and statistical view of the tools required to establish biosimilarity of biological drugs of different complexity -- a must for every developer of biosimilars.
Features:
First comprehensive analysis based on new guidelines and approval packages of several biosimilars
Presents the first approach to challenge FDA in reducing or eliminating any testing in patients.
Provides a comprehensive understanding of the U.S. statutory requirements vis-a-vis the regulatory guidelines
Provides model CQA and Analytical Similarity testing protocols for cytokines and monoclonal antibodies
Allow creation of a fast-to-market pathway to develop biosimilars
About the book
English
Give this book today
It's easy
1 Add to cart and choose Deliver as present at the checkout 2 We'll send you a voucher 3 The book will arrive at the recipient's addressYou might also be interested in
Hi! I'm Libroamiko, your book advisor.
How can I help you?